BMI differences on anticoagulation with bivalirudin vs. heparin during primary PCI: a BRIGHT-4 subanalysis.

ABSTRACT:

Background

Body mass index (BMI) is associated with ischemic and bleeding events in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Procedural anticoagulation with bivalirudin followed by a prolonged high-dose post-PCI infusion was shown in the BRIGHT-4 trial to reduce mortality and major bleeding compared with heparin monotherapy. We aimed to assess the outcomes of bivalirudin compared with heparin in relation to BMI in STEMI patients undergoing primary PCI.

Methods

This prespecified subgroup analysis from the BRIGHT-4 trial evaluated the treatment effects of bivalirudin with a high-dose infusion for 2-4 h after primary PCI compared with heparin monotherapy in 6,016 randomized STEMI patients under

SUBMITTER: Zhang D 

PROVIDER: S-EPMC12482084 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature